RS55449B1 - Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10) - Google Patents

Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10)

Info

Publication number
RS55449B1
RS55449B1 RS20160971A RSP20160971A RS55449B1 RS 55449 B1 RS55449 B1 RS 55449B1 RS 20160971 A RS20160971 A RS 20160971A RS P20160971 A RSP20160971 A RS P20160971A RS 55449 B1 RS55449 B1 RS 55449B1
Authority
RS
Serbia
Prior art keywords
bromo
diamine
pyrimidine
pyrazol
group
Prior art date
Application number
RS20160971A
Other languages
English (en)
Serbian (sr)
Inventor
Gómez Juan Camacho
Palomino Laria Julio Castro
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Publication of RS55449B1 publication Critical patent/RS55449B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RS20160971A 2013-01-24 2014-01-23 Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10) RS55449B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201330082A ES2480341B1 (es) 2013-01-24 2013-01-24 Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10)
PCT/EP2014/051290 WO2014114695A1 (en) 2013-01-24 2014-01-23 New pyrimidine derivatives as phosphodiesterase 10 inhibitors (pde-10)
EP14703553.9A EP2948443B1 (en) 2013-01-24 2014-01-23 New pyrimidine derivatives as phosphodiesterase 10 inhibitors (pde-10)

Publications (1)

Publication Number Publication Date
RS55449B1 true RS55449B1 (sr) 2017-04-28

Family

ID=50071592

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160971A RS55449B1 (sr) 2013-01-24 2014-01-23 Novi derivati pirimidina kao inhibitori fosfodiesteraze 10 (pde-10)

Country Status (23)

Country Link
US (1) US9447095B2 (enExample)
EP (1) EP2948443B1 (enExample)
JP (1) JP6254194B2 (enExample)
KR (1) KR101869144B1 (enExample)
CN (1) CN105008346B (enExample)
AU (1) AU2014209950B2 (enExample)
BR (1) BR112015017678B1 (enExample)
CA (1) CA2897260C (enExample)
CY (1) CY1118552T1 (enExample)
DK (1) DK2948443T3 (enExample)
EA (1) EA026330B1 (enExample)
ES (2) ES2480341B1 (enExample)
HR (1) HRP20161495T1 (enExample)
HU (1) HUE031831T2 (enExample)
LT (1) LT2948443T (enExample)
ME (1) ME02551B (enExample)
MX (1) MX361160B (enExample)
PL (1) PL2948443T3 (enExample)
PT (1) PT2948443T (enExample)
RS (1) RS55449B1 (enExample)
SI (1) SI2948443T1 (enExample)
SM (1) SMT201600428B (enExample)
WO (1) WO2014114695A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
CN107286146B (zh) * 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
CN116836162B (zh) * 2023-05-24 2025-09-05 南方医科大学 吡唑[4,3-c]吡啶类化合物或其药学上可接受的盐及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080221103A1 (en) 2007-03-09 2008-09-11 Orchid Research Laboratories Ltd. New heterocyclic compounds
SI2617420T1 (sl) 2009-05-07 2016-02-29 Forum Pharmaceuticals Inc. Fenoksimetil heterociklične spojine
WO2010138430A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors
US20120082354A1 (en) 2009-06-24 2012-04-05 Koninklijke Philips Electronics N.V. Establishing a contour of a structure based on image information
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
NZ601967A (en) 2010-03-12 2015-03-27 Omeros Corp Pde10 inhibitors and related compositions and methods
US9284301B2 (en) 2010-03-25 2016-03-15 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US8592423B2 (en) 2011-06-21 2013-11-26 Bristol-Myers Squibb Company Inhibitors of PDE10
US9365562B2 (en) 2011-10-06 2016-06-14 Merck Sharp & Dohme Corp. 1,3 substituted azetidine PDE10 inhibitors

Also Published As

Publication number Publication date
ME02551B (me) 2017-02-20
PL2948443T3 (pl) 2017-02-28
PT2948443T (pt) 2016-11-15
CA2897260A1 (en) 2014-07-31
MX2015009627A (es) 2016-04-25
HUE031831T2 (en) 2017-08-28
JP2016505059A (ja) 2016-02-18
CN105008346B (zh) 2018-11-13
EP2948443B1 (en) 2016-08-31
MX361160B (es) 2018-11-28
JP6254194B2 (ja) 2017-12-27
KR20150126601A (ko) 2015-11-12
AU2014209950A1 (en) 2015-08-27
HRP20161495T1 (hr) 2016-12-16
ES2480341B1 (es) 2015-01-22
EP2948443A1 (en) 2015-12-02
CN105008346A (zh) 2015-10-28
ES2611170T3 (es) 2017-05-05
LT2948443T (lt) 2016-12-12
CA2897260C (en) 2018-11-20
BR112015017678B1 (pt) 2023-02-14
US9447095B2 (en) 2016-09-20
KR101869144B1 (ko) 2018-07-19
US20150336953A1 (en) 2015-11-26
EA026330B1 (ru) 2017-03-31
ES2480341A1 (es) 2014-07-25
EA201591369A1 (ru) 2016-01-29
SMT201600428B (it) 2017-01-10
SI2948443T1 (sl) 2016-12-30
AU2014209950B2 (en) 2017-04-20
WO2014114695A1 (en) 2014-07-31
BR112015017678A2 (pt) 2017-07-11
CY1118552T1 (el) 2017-07-12
DK2948443T3 (en) 2016-12-12

Similar Documents

Publication Publication Date Title
RU2559895C2 (ru) Азотосодержащие производные гетероарилов
US9604963B2 (en) Amino-quinolines as kinase inhibitors
JP2020513403A (ja) 置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法
TW200524598A (en) Pharmaceutical compounds
KR20020015060A (ko) 축합 이미다졸 화합물 및 당뇨병 치료약
KR20180118752A (ko) 섬유증의 치료를 위한 신규 화합물 및 그의 약학 조성물
JP2025522274A (ja) Pargの阻害剤
JP2016508135A (ja) カゼインキナーゼ1d/e阻害剤としての新規なピラゾール置換のイミダゾピラジン
TW201309672A (zh) 新穎吲哚、吲唑衍生物或其鹽
WO2012054366A2 (en) Substituted amino-triazolyl pde10 inhibitors
ES3060367T3 (en) New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
EP2948443B1 (en) New pyrimidine derivatives as phosphodiesterase 10 inhibitors (pde-10)
US20140288043A1 (en) Pyrazolopyridine compounds
JP2024528729A (ja) Srpkインヒビター
EA049416B1 (ru) Ингибиторы аутофагии на основе гетероариламинопиримидинамида и способы их применения
JP2024540217A (ja) プロテインキナーゼ、特には、dyrk1a、clk1及び/又はclk4、の阻害剤としてのイミダゾロン誘導体
BRPI0719333B1 (pt) Imidazotriazinas e imidazopirimidinas como inibidores de cinase, composição farmacêutica que as compreende e métodos in vitro